Standout Papers

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patient... 2022 2026 2023 2024248
  1. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
    Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 68 standout
Sub-graph 1 of 22

Citing Papers

Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
2 intermediate papers

Works of Philip He being referenced

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
2022 Standout
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
2020

Author Peers

Author Last Decade Papers Cites
Philip He 271 104 71 263 19 440
Thomas Cheung Yau 245 75 50 273 21 446
J Faintuch 319 97 113 90 24 478
Petros Fessas 335 131 48 161 14 511
Lin Yang 246 118 88 286 11 459
Oxana Crysler 257 60 61 205 24 405
Zhong-Guo Zhou 190 76 78 144 17 378
Vito Longo 274 124 63 81 29 467
Juxiang Xiao 259 151 104 148 14 410
L.-T. Chen 170 114 131 250 19 506
Alexandra Heurgué 150 83 99 311 17 486

All Works

Loading papers...

Rankless by CCL
2026